Business Context and Reporting Period
This Form 8-K reports on the 2015 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on May 1, 2015. The report was filed on May 5, 2015. As of the record date of March 4, 2015, there were 83,990,886 shares issued and outstanding.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
The filing details the outcomes of four specific shareholder votes:
- Director Elections: Stockholders re-elected Dennis A. Ausiello, M.D., John K. Clarke, and Marsha H. Fanucci as Class II directors. The remaining directors (Michael W. Bonney, John M. Maraganore, Steven M. Paul, Paul R. Schimmel, Amy W. Schulman, Phillip A. Sharp, and Kevin P. Starr) continued their terms.
- Stock Incentive Plan: Stockholders approved the Amended and Restated 2009 Stock Incentive Plan.
- Executive Compensation: Stockholders approved, in a non-binding advisory vote, the compensation of the named executive officers.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2015.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is strictly limited to the reporting of voting results.
Key Facts for Investor Verification
- Voting Support: All three Class II director nominees received over 95% of the votes cast "For" (ranging from 93.8% to 95.1% of total votes cast excluding broker non-votes).
- Plan Approval: The Amended and Restated 2009 Stock Incentive Plan was approved with 63,240,685 votes "For" versus 3,073,710 "Against".
- Compensation Vote: The "Say-on-Pay" advisory vote passed with 63,187,787 votes "For" versus 2,899,402 "Against".
- Auditor Ratification: The ratification of PricewaterhouseCoopers LLP received overwhelming support with 71,335,374 votes "For" and only 127,423 "Against".
- Broker Non-Votes: There were 5,152,851 broker non-votes recorded for the director elections, stock plan, and compensation vote.